Daniel Van Plew
2021
Compensation breakdown
Non-Equity Incentive Plan | $930,587 |
---|---|
Option Awards | $4,199,871 |
Salary | $822,800 |
Stock Awards | $2,799,882 |
Other | $20,950 |
Total | $8,774,090 |
Van Plew received $4.2M in option awards, accounting for 48% of the total pay in 2021.
Van Plew also received $930.6K in non-equity incentive plan, $822.8K in salary, $2.8M in stock awards and $21K in other compensation.
Rankings
In 2021, Daniel Van Plew's compensation ranked 1,260th out of 12,415 executives tracked by ExecPay. In other words, Van Plew earned more than 89.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,260 | 90th |
Manufacturing | 448 | 92nd |
Chemicals And Allied Products | 164 | 93rd |
Drugs | 136 | 94th |
Pharmaceutical Preparations | 90 | 94th |
Van Plew's colleagues
We found five more compensation records of executives who worked with Daniel Van Plew at Regeneron Pharmaceuticals in 2021.
2021
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
2021
Andrew Murphy
Regeneron Pharmaceuticals
Executive Vice President, Research
2021
Joseph LaRosa
Regeneron Pharmaceuticals
General Counsel
2021
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
2021
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
News
April 21, 2022
April 23, 2021
April 24, 2020
April 26, 2019